InMed Pharmaceuticals Provides Strategic Update on Drug Development Programs in 2026

Vancouver, BC – InMed Pharmaceuticals Inc. (NASDAQ: INM), a clinical-stage pharmaceutical company focused on small molecule drug candidates targeting CB1/CB2 receptors, has released a comprehensive update on its pharmaceutical pipeline, with significant advancements in its lead programs for Alzheimer’s disease and dry age-related macular degeneration (AMD). The company’s new disclosures contain several price-sensitive updates that investors should carefully consider.

Key Highlights from the Report

• Lead Candidate INM-901 Progressing Toward FDA Engagement: The company has achieved critical preclinical milestones for INM-901, its proprietary, orally bioavailable small molecule drug candidate for Alzheimer’s disease. INM-901 targets neuroinflammation, believed to be a central driver of Alzheimer’s progression. InMed is planning a pre-IND (Investigational New Drug) meeting with the FDA in Q3 2026, with an aim to initiate Phase 1 human clinical trials in 2027.
• INM-901 Demonstrates Multi-Faceted Efficacy in Preclinical Models:
  • Significant reduction in key inflammatory biomarkers and neurodegenerative markers in 5xFAD mouse models.
  • Shows anti-inflammatory effects independent of amyloid-beta or tau pathology, supporting a novel mechanism distinct from many current Alzheimer’s drugs.
  • Demonstrates neuroprotective effects, enhances neuronal regeneration, and leads to behavioral improvements linked to cognitive function and anxiety-related behaviors.
  • Oral formulation achieves anticipated therapeutic levels in large animal studies, suggesting positive pharmacokinetics for eventual clinical use.
  • mRNA data correlates with behavioral findings, underpinning the biological basis for observed effects.
• INM-901 Manufacturing and Regulatory Readiness:
  • Ongoing dose-ranging and exposure studies to support IND-enabling studies.
  • Advancements in drug substance and product development, including formulation and scale-up, to support regulatory studies.
  • Initiation of regulatory and clinical development framework for first-in-human evaluation.
• 2026 Development Priorities for INM-901:
  • Pre-IND meeting with the FDA in Q3 2026.
  • Continuation of IND-enabling pharmacology and toxicology studies.
  • Scale-up of drug manufacturing to support IND submission.
  • Engagement of regulatory and clinical experts to design first-in-human trials.
  • Targeting IND submission and initiation of a Phase 1 clinical trial in 2027, subject to regulatory feedback.
• INM-089 for Dry Age-Related Macular Degeneration (AMD) Advances:
  • INM-089, a small molecule candidate for dry AMD, has completed preclinical studies demonstrating dose proportionality and relevant pharmacological concentrations.
  • Drug manufacturing processes are in place, with further optimization expected ahead of IND submission.
  • Planning for a pre-IND meeting with the FDA in Q4 2026.

Potentially Price-Sensitive Updates for Shareholders

• Clear Pathway Toward Human Trials: The targeting of a pre-IND meeting for INM-901 in Q3 2026 and a Phase 1 trial initiation in 2027 is a significant inflection point. Success in these milestones could substantially de-risk the lead program and enhance shareholder value.
• Novel Mechanism of Action: INM-901’s approach to targeting neuroinflammation, a growing area of consensus in Alzheimer’s research, positions InMed in a differentiated and potentially high-value segment of the market.
• Advancements in Manufacturing and Regulatory Readiness: Progress in drug substance and product development, scale-up, and regulatory planning signal a maturing pipeline and readiness for clinical translation, which are often key drivers of market sentiment and valuation.
• Pipeline Diversification: The development of INM-089 for dry AMD and planning for FDA engagement in Q4 2026 adds another potential value driver and de-risks the company’s portfolio.

What Investors Should Watch For

• FDA Interactions: The outcomes of the planned pre-IND meetings for both INM-901 and INM-089 in the second half of 2026 could be major catalysts.
• IND-Enabling Studies: Successful completion of pharmacology, toxicology, and manufacturing scale-up work will be critical for regulatory submissions and future valuation.
• First-in-Human Data: If the company proceeds on schedule, Phase 1 results for INM-901 could emerge as early as 2027, representing a pivotal moment for the company’s future.

Conclusion

InMed Pharmaceuticals’ 2026 update reveals a disciplined, milestone-rich development plan, with potentially transformative implications for both its Alzheimer’s and dry AMD programs. The company’s focus on neuroinflammation and multi-pathway approaches, alongside its regulatory and manufacturing progress, could materially influence its share price, especially as it approaches key FDA interactions and clinical trial initiations.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Investors should consult the company’s filings with the SEC and seek independent advice before making investment decisions.

View InMed Pharmaceuticals Inc. Historical chart here